Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.

Antiviral research

PubMedID: 26122170

Genebat M, de Pablo-Bernal R, Pulido I, Jiménez-Mejías ME, Martínez O, Pacheco YM, Raffi-El-Idrissi Benhia M, Abad MA, Ruiz-Mateos E, Leal M. Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients. Antiviral Res. 2015;.
Our aim was to analyze the virological response to a combined antiretroviral therapy started after Maraviroc Clinical Test (MCT) in naïve HIV-infected patients. Forty-one patients were exposed to MCT, based on an 8-day MVC monotherapy. If undetectability or a viral load reduction >1 log10 HIV-RNA copies/ml was achieved, a MVC-containing cART was prescribed. Forty patients showed a positive MCT; undetectability after 48weeks on cART was achieved in 34/41 (82. 9%) patients. The result of MCT was compared with a genotypic tropism method and with Trofile®, showing 10. 7% and 18. 75% discordance rates, respectively. MCT is a reliable tool to decide CCR5-antagonists prescription, also in the naïve scenario where most patients show a virological response to MVC independently the tropism result reported by genotypic or phenotypic methods.